AR110113A1 - Anticuerpo anti-selectina y sus usos - Google Patents

Anticuerpo anti-selectina y sus usos

Info

Publication number
AR110113A1
AR110113A1 ARP170103055A ARP170103055A AR110113A1 AR 110113 A1 AR110113 A1 AR 110113A1 AR P170103055 A ARP170103055 A AR P170103055A AR P170103055 A ARP170103055 A AR P170103055A AR 110113 A1 AR110113 A1 AR 110113A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
selectin
selectine
antibody
Prior art date
Application number
ARP170103055A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR110113A1 publication Critical patent/AR110113A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se relaciona con el tratamiento o la prevención de trastornos mediados por la selectina P, y con anticuerpos anti-selectina P o fragmentos de unión de estos, para usar en el tratamiento o la prevención de dichos trastornos. En particular, se relaciona con el tratamiento o la prevención de crisis dolorosas asociadas con la drepanocitosis, y con anticuerpos anti-selectina P o fragmentos de unión de estos, para usar en el tratamiento o la prevención de las crisis dolorosas asociadas con la drepanocitosis.
ARP170103055A 2016-11-03 2017-11-03 Anticuerpo anti-selectina y sus usos AR110113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201618532 2016-11-03

Publications (1)

Publication Number Publication Date
AR110113A1 true AR110113A1 (es) 2019-02-27

Family

ID=62075887

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103055A AR110113A1 (es) 2016-11-03 2017-11-03 Anticuerpo anti-selectina y sus usos

Country Status (2)

Country Link
US (1) US20200055942A1 (es)
AR (1) AR110113A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220636A1 (en) * 2022-05-10 2023-11-16 New York Blood Center, Inc. Drug conditioning regimen for sickle cell disease

Also Published As

Publication number Publication date
US20200055942A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
SV2018005661A (es) Composiciones oligonucleotidicas y sus metodos
NI201500117A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY36687A (es) Anticuerpos contra ox40 y sus usos
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CL2017000806A1 (es) Compuestos anti-tnf
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
UY36550A (es) Oligómeros antisentido de tau y sus usos
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CO6690781A2 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY35399A (es) Conjugados de fármacos con anticuerpos
DOP2013000025A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
GT201700188A (es) Anticuerpos contra tau y sus usos
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
UY31861A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CR20130074A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2012000122A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20160561A (es) Variantes del anticuerpo anti-factor d y sus usos
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias

Legal Events

Date Code Title Description
FB Suspension of granting procedure